Yves G. Pommier

SCLC TumorMiner is a genomics platform that provides molecular classification, biomarker identification, and drug-response analysis for small cell lung cancer using integrated datasets from multiple institutions.

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

The paper presents cryo-EM structures of human TOP1cc bound to eight anticancer drugs, revealing structural differences and insights for drug design.

This study shows SLFN11 is highly expressed in multiple myeloma and normal plasma cells, and its nucleolar translocation in response to bortezomib correlates with drug resistance and therapeutic benefit.

This study shows that HDAC inhibition with entinostat enhances immunotherapy response in SCLC by reprogramming tumor immunology and neuroendocrine status.

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

The paper identifies that DUB inhibitors and RNF168-mediated ubiquitylation drive SLFN11 chromatin recruitment, particularly at promoters, and that this process is suppressed by TAK243.

This study identifies SLFN11 as a suppressor of the ALT telomere maintenance pathway, showing its re-expression reduces ALT activity in cancer cells.

This study identifies PRDX1's role in preventing oxidative damage to the nucleolar genome by maintaining rDNA transcription and ribosome biogenesis.

This study identifies key cellular programs and pathways driving metastatic organotropism in small cell lung cancer using preclinical models and multiomic profiling.

This study identifies TOP3A's role in ALT telomere maintenance, showing its enrichment at ALT telomeres and its impact on TERRA and TERF2 stability.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This paper identifies SEMA7A as a prognostic biomarker in adrenocortical carcinoma using transcriptome data from TCGA and NCI samples, showing its association with poor prognosis and specific signaling pathways.

This study shows that LMNA deficiency in SCLC increases R-loop accumulation, leading to genomic instability and poor patient survival.

This study shows that Top3b loss accelerates lymphoma development and causes immune dysregulation in mice through R-loop accumulation and immune signaling activation.

This study identifies FA-induced DNA-protein crosslinks (DPCs) and discovers that FEN1 repairs them via PARylation, revealing a novel PARP1-FEN1 pathway for DPC repair.

This study shows that Top1MT deficiency in mice leads to severe MASH with liver steatosis, inflammation, and fibrosis after a high-fat diet.

The paper maps genome-wide topoisomerase binding sites to identify TOP3A as a sensor of transcription-replication conflicts.

The paper characterizes two TOP1MT variants in a patient with hypertrophic cardiomyopathy, showing both impair mitochondrial functions but affect different aspects of mtDNA regulation.

This study identifies a 24-protein panel distinguishing TNBC from other breast cancers and shows proteomics improves drug sensitivity predictions.

The paper identifies p97 ATPase as a key player in removing trapped PARP1 from chromatin, enhancing PARPi-induced cytotoxicity in homologous recombination-defective cells.

The paper examines SLFN11 expression in B-cell development and lymphomas, finding it is epigenetically suppressed in germinal center B cells and that epigenetic modifiers enhance its expression, increasing sensitivity to cytosine arabinoside.

The paper identifies a conserved SUMO-Ubiquitin pathway involving PIAS4 and RNF4 that mediates proteasomal degradation of topoisomerase DNA-protein crosslinks in human and yeast cells.

BAMscale processes DNA sequencing datasets to generate normalized peak scores and scaled coverage tracks for visualization.

This study rapidly generates proteomic data for NCI-60 cancer cell lines and identifies drug response determinants by integrating proteomic, genetic, and transcriptomic data.

CellMinerCDB integrates pharmacogenomic data from multiple cancer cell line databases to identify drug response determinants, reproducibility, and novel genomic signatures.